Epcoritamab Shows Promise in Large B-Cell Lymphoma
Epcoritamab elicits durable responses in patients with relapsed or refractory large B-cell lymphoma.
Epcoritamab elicits durable responses in patients with relapsed or refractory large B-cell lymphoma.
The CARMEN regimen appears effective in patients with MYC-rearranged aggressive lymphoma, including those who are HIV-positive.
Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.
Early results appear promising for frontline asciminib in patients with chronic phase chronic myeloid leukemia, according to researchers.
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
First-line bendamustine plus rituximab followed by ASCT and rituximab maintenance appears effective in mantle cell lymphoma.
Researchers sought to compare zanubrutinib with ibrutinib in patients with CLL/SLL.
Researchers sought to determine whether azacitidine plus venetoclax would be effective in patients with high-risk MDS or chronic myelomonocytic leukemia.
Results from the CodeBreak 200, EMPOWER-Lung 1, IPSOS, and ADAURA trials highlight the efficacy of immunotherapy and targeted therapies in non-small cell lung cancer.
Researchers sought to determine the treatment and survival trends for patients with mantle cell lymphoma.